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i n d i a n h e a r t j o u r n a l 6 5 ( 2 0 1 3 ) 2 1 9e2 2 8222patients without baseline “SCD-HeFT criteria” (left ven-
tricular ejection fraction >0.35 or NYHA class I), 125 were
evaluated after 5.5  2 months. Of these 227 patients, 13
(10%) developed “SCD-HeFT criteria” (group B1), 111 (89%)
remained without “SCD-HeFT criteria” (group B2), and 1
(1%) had worsened to NYHA class IV. The 10-year mortal-
ity/heart transplantation and sudden death/sustained
ventricular arrhythmia rate was 57% and 37% in group A1,
23% and 20% in group A2 (p < 0.001 for mortality/heart
transplantation and p e 0.014 for sudden death/sustained
ventricular arrhythmia vs. group A1), 45% and 41% in group
B1 ( p e NS vs. group A1), 16% and 14% in group B2 ( p e NS
vs. group A2), respectively.
Conclusion: Two thirds of patients with idiopathic
dilated cardiomyopathy and “SCD-HeFT criteria” at pre-
sentation did not maintain implantable cardioverter-
defibrillator indications 3e9 months later with optimal
medical therapy. Their long-term outcome was excellent,
similar to that observed for patients who had never met the
“SCD-HeFT criteria.”
1. Perspective
Since the publication of the SCD-HeFT and the DEFINITE
trials, treatment with ICD for the primary prevention of
sudden cardiac death (SCD) has been extended to patients
with idiopathic dilated cardiomyopathy (IDC), who have a
LVEF of 0.35 and who are classified as NYHA II or III (“SCD-
HeFT criteria,” class I B indication). The appropriate timing
for ICD implantation, however, is still uncertain. Current
guidelines suggest that an ICD should be considered in
addition to medical therapy, but many patients are treated
with an ICD without evidence-based indications, mainly
because of newly diagnosed heart failure and before treat-
ment optimization. This study evaluated the proportion of
patients with and without potential indications for ICD
implantation at presentation and the long-term prognosis of
patients with initial ICD indications but who improved after
optimization of medical treatment. It also compared the
long-term outcome of “improved” patients to those main-
taining “SCD-HeFT criteria” and those who never met “SCD-
HeFT criteria.”
This trial included only patients who were not on beta
blockers. After initial assessment, optimization of medical
treatment was achieved with gradually up-titrating doses of
beta blockers and ACEI/ARB at the highest tolerated dose over
a period of 3e9 months.
The main results of the present study are: 1) 50% patients
had SCD-HeFT criteria at first assessment and would have
otherwise received an ICD. 2) 2/3rd of patients with SCD-HeFT
criteria at baseline “improved” and no longermaintained SCD-
HeFT criteria 5.5 months after starting beta blocker and ACEI
treatment. 3) The long-term SCD were similar in “improved”
patients and in those without SCD-HeFT criteria, suggesting
ICD implantation should not be done in most patients with
low LVEF and HF symptoms before optimization of medical
treatment. 4) SCD (4 patients e 2%) was similar in patients
both with and without SCD-HeFT criteria before second
evaluation at 3e9 months, confirming the difficulty of strat-
ifying risk of SCD at first evaluation.This study emphasizes how important is the optimization
of medical therapy in patients initially presenting with ICD
indications and ICD implantation can be avoided in the
majority of such patients. Even in USA, nearly 22.5% of
patients with an ICD did not meet the evidence-based cri-
teria for implantation, mainly because of newly diagnosed
HF (62%). Such unnecessary ICD implantations should be
avoided because of economic issues (especially in a devel-
oping country like India), the risk of complications asso-
ciated with implantation and inappropriate shocks (inw25%
of patients).
What then is the waiting period for ICD implantation after
onset of HF symptoms in patients with LVEF 35%? Well, we
have no clear-cut answer. Data from DEFINITE trial suggest
early ICD implantation (<9months or even<3months) ismore
beneficial while the Cardiomyopathy Trial showed otherwise.
One position could be that at least 3 months are required
for up-titration of doses of beta blockers and ACEI while
waiting for >9 months could well be unnecessary and poten-
tially harmful. So a mean waiting period of 6 months could be
advocated during which we should try and maintain opti-
mally tolerated doses of beta blockers and ACEI/ARB. At 6
months of follow-up, re-assessment of LVEF using Echo-
cardiography/MUGA scan, Holter monitoring to rule out
NSVT, EPS study to rule out inducible VF/sustained VT not
suppressible by a class I antiarrhythmic drug should be done
and patients should be very carefully selected for ICD.
However, a word of caution is that this trial only included
patients with idiopathic dilated cardiomyopathy and the
results cannot be extrapolated to ischemic cardiomyopathy.
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E-mail address: khanal.s@rediffmail.comEvolve trialChronic Kidney Disease (CKD) is now considered a risk
factor for coronary artery disease. Secondary hyper-para-
thyroidism, a disorder of mineral metabolism in patients of
CKD contributes to extra skeletal calcification including car-
diovascular system which is partial responsible for increased
risk of cardiovascular disease.1
It will not be inappropriate to call parathormone as uremic
toxin and level above 600 mg/ml increases the risk of death and
cardiovascular reasons. Cinacalcet is a calcimimetic agent
which acts by allosteric activation of calcium sensing recep-
tors on Parathyroid tissues. This was approved for hyper-
parathyroidism secondary to Chronic Renal Failure (CRF) after
the effect on reducing parathormone specially in patients on
dialysis was shown in multiple randomized trials.2
In EVOLVE Trial (Effect of Cinacalcet on Cardiovascular
Disease in Patients undergoing Dialysis), N Engl J Med.
2012;367:2482e2494, this hypothesis was tested by using
Cinacalcet in addition to conventional therapy for CKD
i n d i a n h e a r t j o u rn a l 6 5 ( 2 0 1 3 ) 2 1 9e2 2 8 223patientswhowere on dialysis. This study comparedCinacalcet
with placebo in 3883 patients undergoing dialysis. Limited
number of interventions are found to improve cardiovascular
health in CKD undergoing dialysis. Secondary hyper-
parathyroidism has emerged as one of the most important
risk factors for cardiovascular disease and thus, high rate of
death and cardiovascular events in end stage renal disease.3
Although this trial result is non-definitive but after adjust-
ment to the baseline characteristics there was nominally sig-
nificant 12% reduction in cardiovascular risk, 15% reduction in
primary composite end point and 17% reduction in mortality.
One has to understand the context of the patients who are
on dialysis, frequently have poor health and high mortality
(20% inUnited States) andmorbidity (median 2 hospitalization
and 12 hospital days per year). Patients have multi organ
involvement with average pill burden of 19. Cinacalcet
reduces parathyroidectomy by 50%. The study includes
Cohorts from various geographic area, race, ethnicity, age and
underlying kidney and cardiovascular diseases.
Analysis adjusted for baseline characteristics on taking
into account the effect of parathyroidectomy and kidney
transplantation a nominally significant reduction on death on
first Myocardial Infarction, hospitalization for unstable
angina, heart failure and peripheral vascular disease (risk
reduction 10e15% and absolute reduction of 2e3%).r e f e r e n c e s
1. Kidney disease improving global outcomes (KDIGO) CKD-MBD
Work Group. Kidney Int Suppl. 2009;76:S1eS130.
2. Cunningham J, et al. Kidney Int. 2005;68:1793.
3. Chertow GM, et al. Am Soc Nephrol. 2007;2:898e905.
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1. Introduction
The enemy of revascularization using primary PCI during
STEMI intervention is risk of distal embolizationwith capillary
plugging which leads to reduced tissue reperfusion. Several
pharmacological agents, as well as mechanical devices (i.e.
manual aspiration catheters/mechanical thrombectomy,
proximal and distal protection devices) were introduced, in
the last years, to reduce the risk of angiographic complica-
tions during percutaneous coronary intervention and to
improve myocardial reperfusion.1,2 Despite the use of these
agents still distal embolization is common which leads to no-
reflow phenomenon.1,2
Recently, the MGuard stent (InspireMD, Tel Aviv, Israel), a
bare metal stent covered by micron level mesh, which allowsto prevent distal embolization by blocking the athero-thrombi
prolapse through the stent struts during deployment.3
Dr. Gregg W. Stone presented the late-breaking findings
from the MASTER study were presented in a late-breaking
session at TCT 2012 that revealed a new stent in STEMI
patients undergoing emergent PCI to increase the rate of com-
plete ST-segment resolution comparedwith conventional BMS
and DES.
2. Objectives
MASTER study sought to evaluate the potential utility of a
novel polyethylene terephthalate micronet mesh-covered
stent (MGuard) in patients with acute ST-segment elevation
myocardial infarction (STEMI) undergoing percutaneous cor-
onary intervention (PCI).
3. Study design
 The MASTER trial is a prospective, multicenter, randomized
study designed to compare the incidence of complete
(70%) ST-segment resolution with PCI using bare metal or
drug-eluting stents (the control arm) versus PCI with the
MGuard stent,measured 60e90min after the last angiogram
(primary endpoint).
 Secondary endpoints include the rates of TIMI flow and
myocardial blush, and clinical outcomes through 1-year
follow-up.
 The study has enrolled 432 patients with STEMI undergoing
primary or rescue angioplasty within 12 h of symptom
onset, and includes sub studies with cardiac magnetic res-
onance imaging and quantitative coronary angiography to
evaluate infarct size, micro vascular obstruction and
angiographic restenosis.
 Study population for trial enrolled a total 433 STEMI patients
who presentedwithin 12 h of symptomonset, at 50 sites in 9
countries.
 These enrolees were randomly assigned to receive com-
mercially available stents (n ¼ 216; 60% BMS; 40% DES) or
MGuard (n ¼ 217). The two groups had equal baseline
characteristics.3
4. Results
 Significantly more patients treated with the MGuard
EPS achieved the primary endpoint of post-procedure
of complete ST resolution (a measure of blood flow
restoration to the heart muscle) compared to control arm
(57.8% vs. 44.7%, p ¼ 0.008), a relative improvement of 29%
[Fig. 2].
 When compared to control, the MGuard EPS showed a sig-
nificant improvement in coronary artery blood flow,
including (1): superior rates of restoring normal blood flow
(TIMI 3 flow) (91.7% vs. 82.9%, p ¼ 0.006, a relative
improvement of 10.6%); and (2) significantly less incomplete
blood flow (TIMI 0/1 flow) post PCI (1.8% vs. 5.6%, p ¼ 0.01, a
relative improvement of 67.9%).
 The trial showed a trend toward lower mortality (0% vs.
1.9%, p ¼ 0.06) at 30 days and smaller infarct size as
